The Foundation for Angelman Syndrome Therapeutics (FAST) isn’t waiting around; we’re doing the hard, early work to make drug development possible.  We’re actively building a pipeline where none existed. FAST is one of the few rare disease organizations taking this kind of leadership role. 

FAST doesn’t just fund research, we shape it. We partner with scientists, fund promising research, and help guide projects toward clinical trials. 

With your help, we are not just hoping for progress. We are making it happen.